Samsung Epis, KR70126Z0002

Samsung Epis Holdings stock: subsidiary approves KRW 104.3 billion dividend

Published on 11/20/2026 at 02:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Samsung Epis Holdings stock will receive an interim cash distribution from its wholly owned biotech subsidiary. Payment is scheduled for December 18.

Dividend supports holding company funding

  • Samsung Bioepis approved the interim cash distribution at its November 11 board meeting.
  • The record date is December 4, with payment scheduled for December 18.
  • Samsung Epis Holdings plans to use the proceeds for operating flexibility and potential investments in novel drugs and biosimilars.
Samsung Epis, KR70126Z0002, Illustration mit AI erstellt.

Samsung Bioepis approved an interim cash dividend of KRW 104.3 billion for Samsung Epis Holdings at a board meeting on November 11, according to the regulatory filing published on November 12. Samsung Epis Holdings owns all of Samsung Bioepis, so the full distribution will flow to the holding company.

Funding arrives before December payment

The dividend is set at KRW 5,043 per common share. December 4 is the record date, and payment is scheduled for December 18. The filing states that Samsung Bioepis is an unlisted subsidiary, so no market dividend yield was calculated.

Samsung Epis Holdings said the proceeds are intended to strengthen financial flexibility and support operating activities. The holding company is also reviewing uses linked to future growth in novel drugs and biosimilars, keeping the allocation relevant to investors assessing the group after its corporate separation.

Holding structure centers on biopharma

Samsung Epis Holdings is a South Korean biotechnology holding company focused on biopharmaceutical innovation and the development and commercialization of biosimilar medicines. Its wholly owned Samsung Bioepis subsidiary supplies the core operating platform, while the parent directs capital toward operations, novel-drug opportunities and additional biosimilar programs. The structure is more specialized than diversified pharmaceutical groups such as Sandoz and Teva, which also operate in the global biosimilar market.

Samsung Epis Holdings at a glance

  • Company: Samsung Epis Holdings
  • ISIN: KR70126Z0002
  • Core subsidiary: Samsung Bioepis
  • Ownership: 100 percent of Samsung Bioepis
  • Dividend: Interim cash dividend, KRW 104.3 billion total
  • Record date: December 4, 2026
  • Scheduled payment: December 18, 2026

The South Korean market backdrop can be followed through the KOSPI Composite.

More news and analyses on Samsung Epis Holdings stock.

Disclaimer...
en | KR70126Z0002 | SAMSUNG EPIS | boerse | 70538265 | bgmi